Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
